A Retrospective Analysis of Safety and Efficacy of Weekly Nab-paclitaxel As Second-line Chemotherapy in Elderly Patients with Advanced Squamous Non-small-cell Lung Carcinoma

Overview

Journal Clin Interv Aging

Publisher Dove Medical Press

Specialty Geriatrics

Date 2016 Mar 2

PMID 26929611

Citations 9

Authors

Feng Jin

Hui Zhu

Fang Shi

Li Kong

Jinming Yu

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous non-small-cell lung cancer (NSCLC).

Patients And Methods: We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monotherapy as a second-line treatment from January 2010 to March 2014. A dose of 100 mg/m(2) nab-paclitaxel was administered weekly on days 1, 8, and 15, followed by 1 week of rest. The protocol was maintained for at least two cycles.

Results: The overall response rate (ORR) and the disease control rate (DCR) were 21.43% (9/42) and 47.62% (20/42), respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.6 and 10.9 months, respectively. In the subgroup analysis, there was no significant difference in ORR, DCR, PFS, and OS, accounting for the first-line therapy factors (taxane agent, radiotherapy, or surgery). There was a statistically significant difference in DCR for stages III and IV (62.96% vs 20%, P=0.008), but there was no such difference in either PFS or OS. The ORR of 29 patients receiving more than three cycles of treatment was higher than that of those receiving less than three cycles of treatment (31.03% vs 0%, P=0.038), and there was a significant difference in PFS (7.6 vs 4.9 months, P=0.004) and OS (11.7 vs 8.9 months, P=0.002). No hypersensitivity reactions or treatment-related grade 4 adverse events were reported.

Conclusion: Nab-paclitaxel monotherapy administered weekly at a dose of 100 mg/m(2) is shown to be an effective and safe regimen for elderly patients with relapsed squamous NSCLC, especially for patients with stage III disease or good performance status.

Citing Articles

Efficacy and Safety of Nanoadministration in the Treatment of Non-Small-Cell Lung Cancer Is Good to Some Extent: A Systematic Review and Meta-Analysis.

Han R, Guan Y, Li M, Xu A, Wu D, Li P J Oncol. 2022; 2022:9017198.

PMID: 35300346 PMC: 8923769. DOI: 10.1155/2022/9017198.

Long non-coding RNA H19 and the underlying epigenetic function in response to DNA damage of lung cancer cells.

Wang D, Sun Y, Lin L, Sang Y, Yang F, Zhang J Am J Transl Res. 2021; 13(6):5835-5850.

PMID: 34306329 PMC: 8290785.

Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen.

Hao X, Zhu Y, Mu Y, Wang S, Li J, Xing P J Cancer. 2020; 11(21):6421-6428.

PMID: 33033525 PMC: 7532494. DOI: 10.7150/jca.47072.

Multiline treatment of advanced squamous cell carcinoma of the lung: A case report and review of the literature.

Yang X, Peng P, Zhang L World J Clin Cases. 2019; 7(14):1899-1907.

PMID: 31417937 PMC: 6692274. DOI: 10.12998/wjcc.v7.i14.1899.

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.

Xing P, Zhu Y, Shan L, Chen S, Hao X, Li J Oncotarget. 2017; 8(50):87442-87454.

PMID: 29152093 PMC: 5675645. DOI: 10.18632/oncotarget.21103.

References

Palumbo R, Sottotetti F, Trifiro G, Piazza E, Ferzi A, Gambaro A . Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Devel Ther. 2015; 9:2189-99. PMC: 4404936. DOI: 10.2147/DDDT.S79563. View

Goto Y, Sekine I, Yamada K, Nokihara H, Yamamoto N, Kunitoh H . Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients. J Thorac Oncol. 2008; 3(4):412-6. DOI: 10.1097/JTO.0b013e318168d1f1. View

Joerger M . Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol. 2014; 11(5):691-702. DOI: 10.1517/17425255.2015.983074. View

Wiedenmann N, Valdecanas D, Hunter N, Hyde S, Buchholz T, Milas L . 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res. 2007; 13(6):1868-74. DOI: 10.1158/1078-0432.CCR-06-2534. View

Zheng Q, Yao Y, Nan K . Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases. J Biomed Res. 2013; 26(3):159-64. PMC: 3596065. DOI: 10.7555/JBR.26.20110106. View

Aapro M, Tjulandin S, Bhar P, Gradishar W . Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast. 2011; 20(5):468-74. DOI: 10.1016/j.breast.2011.07.005. View

Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Goksel T . Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384(9944):665-73. DOI: 10.1016/S0140-6736(14)60845-X. View

Yardley D . nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013; 170(3):365-72. DOI: 10.1016/j.jconrel.2013.05.041. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

10.

Rizvi N, Riely G, Azzoli C, Miller V, Ng K, Fiore J . Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2008; 26(4):639-43. DOI: 10.1200/JCO.2007.10.8605. View

11.

Green M, Manikhas G, Orlov S, Afanasyev B, Makhson A, Bhar P . Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006; 17(8):1263-8. DOI: 10.1093/annonc/mdl104. View

12.

Socinski M, Evans T, Gettinger S, Hensing T, Sequist L, Ireland B . Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e341S-e368S. PMC: 4694611. DOI: 10.1378/chest.12-2361. View

13.

Langer C, Hirsh V, Ko A, Renschler M, Socinski M . Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment. Clin Lung Cancer. 2015; 16(2):112-20. DOI: 10.1016/j.cllc.2014.09.003. View

14.

Simon G . nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update. Clin Lung Cancer. 2014; 15(6):391-7. DOI: 10.1016/j.cllc.2014.07.003. View

15.

Socinski M, Langer C, Okamoto I, Hon J, Hirsh V, Dakhil S . Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol. 2012; 24(2):314-321. DOI: 10.1093/annonc/mds461. View

16.

Huang T, Campbell T . Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev. 2011; 38(6):613-7. DOI: 10.1016/j.ctrv.2011.10.008. View

17.

Garassino M, Martelli O, Broggini M, Farina G, Veronese S, Rulli E . Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013; 14(10):981-8. DOI: 10.1016/S1470-2045(13)70310-3. View

18.

Socinski M, Bondarenko I, Karaseva N, Makhson A, Vynnychenko I, Okamoto I . Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012; 30(17):2055-62. DOI: 10.1200/JCO.2011.39.5848. View

19.

Sun Y, Wu Y, Zhou C, Zhang L, Liu X, Yu S . Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study. Lung Cancer. 2012; 79(2):143-50. DOI: 10.1016/j.lungcan.2012.10.015. View

20.

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View